Wilson's disease affects an estimated 1 in 30,000 people and is highly treatable when caught early, yet delayed diagnosis can lead to irreversible liver failure, neurologic disability, or death. Confirmed cases have been reported in patients in their 70s and 80s, and late-onset disease often presents with neurologic or psychiatric findings rather than obvious hepatic disease, so age alone should never exclude testing. Maintaining a low threshold for ceruloplasmin and 24-hour urine copper testing in unexplained hepatic, neurologic, or psychiatric presentations is among the highest-value clinical actions a primary care team can take.
AAVBC's Wilson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity for confirmed Wilson disease and its systemic manifestations, HCC/RAF V28 mapping, diagnostic thresholds using the Leipzig Score and New Wilson Index, MEAT documentation standards, therapy escalation by disease phase, medication safety for chelation and zinc therapy, comorbidity screening, and referral and follow-up timing. Grounded in AASLD 2022 guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize copper overload across its hepatic, neurologic, and psychiatric presentations and document it precisely, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Wilson's disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Wilson's disease affects an estimated 1 in 30,000 people and is highly treatable when caught early, yet delayed diagnosis can lead to irreversible liver failure, neurologic disability, or death. Confirmed cases have been reported in patients in their 70s and 80s, and late-onset disease often presents with neurologic or psychiatric findings rather than obvious hepatic disease, so age alone should never exclude testing. Maintaining a low threshold for ceruloplasmin and 24-hour urine copper testing in unexplained hepatic, neurologic, or psychiatric presentations is among the highest-value clinical actions a primary care team can take.
AAVBC's Wilson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity for confirmed Wilson disease and its systemic manifestations, HCC/RAF V28 mapping, diagnostic thresholds using the Leipzig Score and New Wilson Index, MEAT documentation standards, therapy escalation by disease phase, medication safety for chelation and zinc therapy, comorbidity screening, and referral and follow-up timing. Grounded in AASLD 2022 guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize copper overload across its hepatic, neurologic, and psychiatric presentations and document it precisely, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Wilson's disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
